EpCAM-Binding FN3 Domains for Targeted Cancer Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies for targeting EpCAM, a transmembrane glycoprotein involved in tumorigenesis and metastasis, lack high-affinity and specific non-antibody proteins that can efficiently bind to EpCAM for targeted drug delivery and cancer treatment.
Innovation Solution
Development of fibronectin type III (FN3) domains that specifically bind to EpCAM, which are recombinant, non-naturally occurring polypeptides, capable of high-affinity binding with a dissociation constant of 1×10−13 M or less, and can be conjugated to detectable labels or therapeutic agents for targeted delivery and imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies or antibody fragments are used to target EpCAM, then high affinity and specificity are achieved, but the molecule size is large and requires complex production systems
Solution Approach 1:
The patent creates simplified copies of the antibody binding function using FN3 domains. These domains replicate the target recognition capability of antibodies against EpCAM but with a much simpler protein structure that can be produced in prokaryotic systems, eliminating the need for complex mammalian cell culture infrastructure
Solution Approach 2:
The invention extracts only the essential binding function from the complex antibody structure. By using FN3 domains that contain just the binding domain without the full antibody structure, the patent achieves EpCAM targeting with a minimal protein structure that is easier to produce and modify
2Reliability
If traditional antibodies are used for drug delivery, then target specificity is improved, but tissue penetration efficiency is reduced due to large size
Solution Approach 1:
The FN3 domains create a simplified copy of the antibody binding function with reduced molecular size. This smaller structure maintains EpCAM targeting specificity while enabling more efficient diffusion and penetration into tumor tissues compared to full-size antibodies
3Ease of manufacture
If non-antibody proteins are engineered to bind EpCAM, then ease of production and conjugation is improved, but high-affinity binding capability may be compromised
Solution Approach 1:
The patent optimizes the FN3 domain sequences and structural parameters to achieve high-affinity binding to EpCAM. By carefully selecting and optimizing the amino acid sequences in the FN3 domains, the invention achieves dissociation constants in the low picomolar range, matching or exceeding antibody affinity while maintaining production simplicity
Solution Approach 2:
The invention creates composite molecular structures by conjugating FN3 domains to therapeutic agents, diagnostic labels, or other functional moieties. This composite approach combines the high-affinity binding capability of the optimized FN3 domains with the desired therapeutic or diagnostic function, achieving both high reliability and ease of manufacture
Data Source
AI summary
The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind EpCAM, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the molecules.